Cargando…

Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells

Among herbal medicines, magnolia bark extract, particularly its components honokiol (Hono) and magnolol (Mag), has been widely documented to have antineoplastic properties. The present study aimed to evaluate the synergism of Hono and Mag in bladder cancer therapy both in vitro and in vivo. Treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hisao-Hsien, Chen, Ying, Changchien, Chih-Ying, Chang, Hsin-Han, Lu, Pei-Jyun, Mariadas, Heidi, Cheng, Yu-Chen, Wu, Sheng-Tang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677562/
https://www.ncbi.nlm.nih.gov/pubmed/33240083
http://dx.doi.org/10.3389/fphar.2020.549338
_version_ 1783612001322270720
author Wang, Hisao-Hsien
Chen, Ying
Changchien, Chih-Ying
Chang, Hsin-Han
Lu, Pei-Jyun
Mariadas, Heidi
Cheng, Yu-Chen
Wu, Sheng-Tang
author_facet Wang, Hisao-Hsien
Chen, Ying
Changchien, Chih-Ying
Chang, Hsin-Han
Lu, Pei-Jyun
Mariadas, Heidi
Cheng, Yu-Chen
Wu, Sheng-Tang
author_sort Wang, Hisao-Hsien
collection PubMed
description Among herbal medicines, magnolia bark extract, particularly its components honokiol (Hono) and magnolol (Mag), has been widely documented to have antineoplastic properties. The present study aimed to evaluate the synergism of Hono and Mag in bladder cancer therapy both in vitro and in vivo. Treatment with Mag alone at concentrations up to 80 μM failed to have an antiproliferative effect. In contrast, the combination of Hono and Mag at 40 μM decreased viability, caused cell cycle arrest and enhanced the proportion of Annexin V/7AAD-positive cells. Moreover, Mag with Hono at 40 μM induced caspase 3-dependent apoptosis and autophagy. Neither Hono nor Mag alone had an anti-migratory effect on bladder cancer cells. In contrast, Hono and Mag at 20 μM inhibited the motility of TSGH8301 and T24 cells in wound-healing and Transwell assays. The above phenomena were further confirmed by decreased phosphorylated focal adhesion kinase (p-FAK), p-paxillin, integrin β1, and integrin β3 protein levels. In a nude mouse xenograft model, Mag/Hono administration preferentially retarded T24 tumor progression, which was consistent with the results of cellular experiments. Current findings suggest Hono and Mag treatment as a potential anticancer therapy for both low- and high-grade urothelial carcinoma.
format Online
Article
Text
id pubmed-7677562
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76775622020-11-24 Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells Wang, Hisao-Hsien Chen, Ying Changchien, Chih-Ying Chang, Hsin-Han Lu, Pei-Jyun Mariadas, Heidi Cheng, Yu-Chen Wu, Sheng-Tang Front Pharmacol Pharmacology Among herbal medicines, magnolia bark extract, particularly its components honokiol (Hono) and magnolol (Mag), has been widely documented to have antineoplastic properties. The present study aimed to evaluate the synergism of Hono and Mag in bladder cancer therapy both in vitro and in vivo. Treatment with Mag alone at concentrations up to 80 μM failed to have an antiproliferative effect. In contrast, the combination of Hono and Mag at 40 μM decreased viability, caused cell cycle arrest and enhanced the proportion of Annexin V/7AAD-positive cells. Moreover, Mag with Hono at 40 μM induced caspase 3-dependent apoptosis and autophagy. Neither Hono nor Mag alone had an anti-migratory effect on bladder cancer cells. In contrast, Hono and Mag at 20 μM inhibited the motility of TSGH8301 and T24 cells in wound-healing and Transwell assays. The above phenomena were further confirmed by decreased phosphorylated focal adhesion kinase (p-FAK), p-paxillin, integrin β1, and integrin β3 protein levels. In a nude mouse xenograft model, Mag/Hono administration preferentially retarded T24 tumor progression, which was consistent with the results of cellular experiments. Current findings suggest Hono and Mag treatment as a potential anticancer therapy for both low- and high-grade urothelial carcinoma. Frontiers Media S.A. 2020-11-06 /pmc/articles/PMC7677562/ /pubmed/33240083 http://dx.doi.org/10.3389/fphar.2020.549338 Text en Copyright © 2020 Wang, Chen, Changchien, Chang, Lu, Mariadas, Cheng and Wu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Hisao-Hsien
Chen, Ying
Changchien, Chih-Ying
Chang, Hsin-Han
Lu, Pei-Jyun
Mariadas, Heidi
Cheng, Yu-Chen
Wu, Sheng-Tang
Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells
title Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells
title_full Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells
title_fullStr Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells
title_full_unstemmed Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells
title_short Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells
title_sort pharmaceutical evaluation of honokiol and magnolol on apoptosis and migration inhibition in human bladder cancer cells
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677562/
https://www.ncbi.nlm.nih.gov/pubmed/33240083
http://dx.doi.org/10.3389/fphar.2020.549338
work_keys_str_mv AT wanghisaohsien pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells
AT chenying pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells
AT changchienchihying pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells
AT changhsinhan pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells
AT lupeijyun pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells
AT mariadasheidi pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells
AT chengyuchen pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells
AT wushengtang pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells